ChemotherapyFDA-approvedSecond-line
Jevtana
Generic name: cabazitaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 22% of men with metastatic prostate cancer achieved an objective response, with median overall survival of approximately 15 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Cabazitaxel vs Lu-PSMA in Prostate Cancer: Cost and Effectiveness Compared | Prostate Cancer | phase-3 | Lu-PSMA demonstrated improved PSA response (66% vs 37%) and progression-free survival (HR = 0.63). | Source → |
| Combining Two Drugs May Improve Treatment for Aggressive Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Taxane Allergy: Unexpected Reaction to Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Cabazitaxel Dosage May Affect Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-3 | The OS effect of C25 increased with risk quartiles: -0.07 months (95% CI, -1.60 to 1.46) in the lowest risk quartile and 1.67 months (95% CI, 0.25 to 3.10) in the highest risk quartile. | Source → |
| Severe Neutropenia Risk in Prostate Cancer Patients on Cabazitaxel | Prostate Cancer | observational | — | Source → |
| New Nanoparticle Delivery System for Prostate Cancer Treatment | Prostate Cancer | animal-study | The high-dose CTX-NP group showed a tumor inhibition rate of 79.48%. | Source → |
| New Strategy to Combat Ovarian Cancer Resistance Identified | Ovarian Cancer | lab-study | — | Source → |
| Cabazitaxel Side Effect: Ureteritis in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Cabazitaxel Efficacy in Very Elderly Prostate Cancer Patients | Prostate Cancer | observational | There was no significant difference in therapeutic efficacy between patients under 80 and those 80 or older. | Source → |
| Lu-PSMA Therapy Compared to Cabazitaxel in Advanced Prostate Cancer | Prostate Cancer | observational | Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for Lu-PSMA versus cabazitaxel. | Source → |
| Lu-177 PSMA Treatment Compared in Prostate Cancer Study | Prostate Cancer | phase-3 | The Lu-177 PSMA treatment groups in TheraP and VISION had similar OS (HR, 0.92 [95% CI, 0.70-1.19]). | Source → |
| Enhancing Cancer Treatment with Fatty Acids | Prostate Cancer | lab-study | Dextran-GLA-CTX exhibited the strongest antitumor activity. | Source → |
| Link Found Between Resistance to Two Prostate Cancer Drugs | Prostate Cancer | lab-study | — | Source → |
| Cabazitaxel Efficacy in Prostate Cancer Patients | Prostate Cancer | phase-3 | PSA-RR ≥ -50% was 26% (12/48) and BSI-change rate ≥ -50% was 17% (8/41). | Source → |
| Docetaxel Response Affects Cabazitaxel Sensitivity in Prostate Cancer | Prostate Cancer | observational | None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. | Source → |
| Lab Study on Prostate Cancer Cells' Resistance to Treatment | Prostate Cancer | lab-study | — | Source → |
| Genetic Variants May Affect Prostate Cancer Treatment | Prostate Cancer | lab-study | The hazard ratio for -rs151352 was 0.52, and -rs1341164 was 0.53, indicating better overall survival. | Source → |
| Long-term use of cabazitaxel for prostate cancer treatment | Prostate Cancer | observational | — | Source → |
| Cabazitaxel treatment may help fight prostate cancer by boosting immune response | Prostate Cancer | lab-study | — | Source → |
| New Potential Treatment for Prostate Cancer Resistant to Cabazitaxel | Prostate Cancer | lab-study | — | Source → |
| New Delivery System for Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Cabazitaxel Prodrug Nanoparticles Show Promise in Cancer Therapy | Melanoma | lab-study | — | Source → |
| Cabazitaxel's Effect on Prostate Cancer Cells | Prostate Cancer | lab-study | CAB exerted considerably cytotoxic and apoptotic effects on PC-3 mCRPC cells (p < 0.05). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.